Interferon treatment of cirrhotic patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 4, Issue 2, 1997, Pages 81-91

  Idilman, R ^a,b,c   De Maria, N ^a   Colantoni, A ^a   Dokmeci, A ^b   Van Thiel, D H ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Hepatitis C virus; Interferon

Indexed keywords

INTERFERON;

CHRONIC DISEASE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; REVIEW;

CHRONIC DISEASE; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS;

EID: 0031086205     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1997.tb00209.x     Document Type: Review

References (75)

1. Smith DB, Pontisso P. Heterogeneity of hepatitis C virus. Bailliere's Clin Gastroenterol 1996; 10: 243-256.
2. Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F. Long-term follow-up of acute and chronic non-A, non-B hepatitis. Gut 1982: 23: 270-275.
3. Barrera JM, Bruguera M, Ercilla MG et al. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers. Ann Intern Med 1991; 115: 596-600.
4. Alter MJ, Sampliner RE. Hepatitis C. N Engl J Med 1989; 321: 1538-1540.
5. Margolis H. Epidemiology and control of viral hepatitis. Presented at the 1993 AASLD. Postgraduate course Syllabus, Chicago, Illinois, USA.
6. Esteban JI. Hepatitis C: Progression to chronicity. Proceedings of the Second International Symposium on HCV. Los Angeles, California, USA. November, 1990, p30.
7. Viladomiu L, Genesca J, Esteban JI et al. Interferon alpha in acute post-transfusion hepatitis C. Hepatology 1992; 15: 767-769.
8. Hopf U, Moller B, Kuther D et al. Long term follow-up of posttransfusion hepatitis and frequency of circulation antibodies to hepatitis C virus. J Hepatol 1990; 10: 69-76.
9. Alter HJ. Chronic sequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, eds. Current Respectives in Hepatology. New York: Plenium Publishing. 1989: 83-97.
10. Mattson L. Chronic non-A, non-B hepatitis. Scand J Infect Dis 1989; 59 (Suppl): 3-55.
11. Detre K, Wei Y, Lombardero M et al. Liver transplantation for chronic viral hepatitis. In: AASLD Symposium on viral hepatitis and liver transplantation. Reston, VA (USA) 1995; A24-A26.
12. Alter HJ, Hoofnagle JH. Non-A, non-B: Observations on the first decade. In: Vyas GN, Dienstrg JL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. Orlando, FL: Gruere & Stratton, 1984: 345-354.
13. Degos F, Maisonhcuve P, Thiers V et al. Neonatal transmission of HCV from mother with chronic hepatitis. Lancet 1991; 338: 758.
14. Sherlock S. Chronic hepatitis C. Dis Month 1994; 40: 117-196.
15. Everthart JE, Di Bisceglie AM, Murray LM et al. Risk for non-A, non-B hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112: 544-545.
16. Akahane Y, Aikawa T, Sugai Y, Tsuda F, Okamoto H, Mishiro S. Transmission of HCV between spouses. Lancet 1992; 339: 1059-1060.
17. Saracco G, Rosina F, Torrani MR, Lattore V, Chiandussi L. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11: S43-S49.
18. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340.
19. Levrero M, Tagger A, Balsano C et al. Antibodies to HCV in patients with hepatocellular carcinoma. J Hepatol 1991; 12: 60-63.
20. Simonetti RG, Camma C, Fiorello F et al. HCV infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992; 116: 97-102.
21. Wiranoswska-Stewart M, Stewart WE. Determination of human leukocyte population involved in production of interferons alpha and gamma. J Interferon Res 1981; 1: 233-244.
22. Zoon KC, Arnheiter H. Studies of interferon receptors. Pharm Ther 1984; 24: 259-278.
23. Lengyel P. Mechanism of interferon action: The 2′-5′ A Synthetase-RNase L Pathway. In: Gresser I, ed. Interferon 3. New York: Academic Press, 1981: 77-99.
24. Davis GL, Hoofnagle JH. Interferon in viral hepatitis: Role in pathogenesis and treatment. Hepatology 1986; 6: 1038-1041.
25. Taniguchi T. Regulation of cytokine gene expression. Annu Rev Immunol 1988; 6: 439-464.
26. Beresini MH, Lempert MJ, Epstein LB. Overlapping polypeptide induction in human fibroblasts in response to treatment with interferon alpha, interferon gamma. J Immunol 1988; 140: 485-493.
27. Brouwer JT, Nevens F, Kleter GEM, Elewaut A, Adler M. Treatment of chronic hepatitis C. Hepatol 1993; 18: 110A.
28. Sherlock S. Combination antiviral therapy in chronic hepatitis C. J Hepatol 1995; 23: S1-S2.
29. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991; 24: 219-239.
30. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139-1146.
31. Main J. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. J Hepatol 1995; 23: S32-S36.
32. Chemello L, Cavelletto L, Bernardinello E, Guido M, Pontisso P. The effect of interferon alpha and ribavirin therapy in naïve patients with chronic hepatitis C. J Hepatol 1995;23:S8-S12.
33. Davis GL. Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C. Gut 1993; 34 (Suppl): 109-111.
34. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
35. Gurakar A, Fagiuoli S, Hassanein T, Ersoz S, Van Thiel DH. Prophylactic interferon-alpha therapy following liver transplantation. Eur J Gastroenterol Hepatol 1994; 6: 429-432.
36. Colantoni A, De Maria N, Fagiuoli S, Van Thiel DH. Liver transplantation in virus-induced chronic liver disease. Bailliere's Clin Gastroenterol 1996; 10: 375-388.
37. Takahashi M, Yamada G, Miyamato R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240-243.
38. Jouet P, Roudot-Thoraval F, Dhumeax D, Metreau JM. Comparative efficacy of interferon alpha in cirrhotic and non-cirrhotic patients with non-A, non-B hepatitis. Gastroenterology 1994; 106: 686-690.
39. Camma C, Craxi A, Tine F, Almasio P, Di Marco V, Lo Iacono O. Predictors of response to alpha interferon in chronic hepatitis C. J Hepatol 1992; 17: S20.
40. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP. Prediction of the response of chronic hepatitis C to interferon alpha. Gut 1993; 34: 1714-1717.
41. Yamada G, Takahashi M, Miyamato R, Tsuji T, Yoshizawa H, Okamoto H. Prediction of interferon effect in chronic hepatitis C by both quantification and genotyping of HCV-RNA. Dig Dis Sci 1994; 39: 441.
42. Tsubata A, Chayama K, Ikeda K, Yasuji A, Koida I. Factors predictive of response to interferon therapy in HCV infection. Hepatology 1994; 19: 1088-1094.
43. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon alpha therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1273-1280.
44. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-2156.
45. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-415.
46. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321: 1501-1506.
47. Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89: 681-686.
48. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
49. Caporaso N, Suozzo R, Morisco F, D Antonio M, Romano M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis. Ital J Gastroenterol 1993; 25: 482-486.
50. Van Thiel DH, Friedlander L, Fagiuoli S, Molloy PJ, Kania RJ. The Oklahoma-Pittsburgh experience with interferon α in the treatment of HCV disease. J Oklahoma State Med Assoc 1995; 88: 4.
51. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ. Interferon alpha can be used successfully in patients with hepatitis C virus positive chronic hepatitis who have a psychiatric illness. Eur J Gastro-Hepatol 1995; 7: 165-168.
52. Hassner A, Kletter Y, Shlag D, Yedvab M, Aronson M, Shibolet S. Impaired monocyte function in liver cirrhosis. Br Med J 1981; 282: 1262-1263.
53. Lau JYN, Davis GL, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between virologic and biochemical response to interferon alpha therapy in chronic hepatitis C virus infection. Lancet 1993; 342: 1208-1209.
54. Kishihari Y, Hayashi J, Yoshimura E, Yamaji K, Nakashima K. IL-1b and TNF-a produced by peripheral blood mononuclear cells before and during IFN therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 315-321.
55. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L. Excessive in vitro bacterial lipopolysaccaride-induced production of monokines in cirrhosis. Hepatology 1990; 11: 628-634.
56. Pardo M, Castillo I, Navas S, Carreno V. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony stimulating factor plus recombinant intcrferon alpha. J Med Virol 1995; 45: 439-444.
57. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619-624.
58. Martell M, Esteban JI, Quer J, Genesca J, Weiner A. HCV circulates as a population of different but closely related genomes. J Virol 1992; 66: 3225-3229.
59. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
60. Camps J, Castilla A, Ruiz J, Civeria MP, Prieto J. Randomised trial of lymphoblastoid alpha interferon in chronic hepatitis C. J Hepatol 1993; 19: 390-396.
61. Camps J, Garcia N, Riezu-Boj JI, Civeria MP, Jesus P. Ribavirin in the treatment of chronic hepatitis C unresponsive alpha interferon. J Hepatol 1993; 19: 408-412.
62. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A. α Interferon in the treatment of chronic viral hepatitis. J Hepatol 1993; 18: 112-118.
63. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G. Hepatitis C viremia in chronic liver disease. Hepatology 1994; 19: 273-279.
64. Serfaty L, Giral P, Loria A, Andreani T, Legendre C. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
65. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995; 45: 348-353.
66. Olynyk JK, Redy KR, Di Bisceglie MA, Jeffers LJ, Parker TI. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109.
67. Di Bisceglie MA, Conjeewaram HS, Fried MW, Sallie R, Park Y. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995; 123: 897-903.
68. Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha interferon and ribavirin treatment in chronic hepatitis C. Scand J Infect Dis 1995; 27: 325-329.
69. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 30-35.
70. Pozzato G, Moretti M, Saveria L, Sasso F, Kaneko S. Interferon therapy in chronic hepatitis C virus. J Med Virol 1995; 45: 445-450.
71. Puig P, Dussaix E, Altman C, Lavel C, Stuyver L. Host and viral characteristics affecting the response to interferon therapy in chronic hepatitis C. Eur J Gastro-Hepatol 1995; 7: 335-340.
72. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S. Lymphoblastoid interferon therapy in chronic hepatitis C. Liver 1995; 15: 20-24.
73. Akahane Y, Miyazaki Y, Naitoh S, Takeda K, Tsuda F. Cold activation of complement for monitoring the response to interferon in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 319-327.
74. Shiffman ML, Hofmann CM, Luketic AC, Sanyal AR, Contos MJ. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996; 24: 21-26.
75. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon a 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 149-154.